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Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs), a popular class of antidepressants, may increase breast
cancer risk by stimulating the secretion of prolactin, a potential tumour promoter. We evaluated the effects of
duration of SSRI use, cumulative dose, and latency on the risk of breast cancer by conducting a population-based
case-control study utilizing Saskatchewan health databases.
Methods: Cases included 1,701 women with primary invasive breast cancer diagnosed from 2003 to 2006, and
controls consisted of 17,017 women, randomly selected from the population registry. Use of SSRIs was compiled
using the Saskatchewan prescription database. Unconditional logistic regression was conducted to evaluate the
impact of duration of combined SSRI use (total number of prescriptions dispensed), cumulative dose (total dosage
received) and timing of use (two or more years, two to seven years and more than seven years prior to index
date) on the risk of breast cancer.
Results: Overall, SSRI use was not associated with an increased risk of breast cancer regardless of our definition of
cumulative use (total number of prescriptions dispensed and total dosage). In addition, our results indicate that
prolonged SSRI use does not have a latent effect on breast cancer risk. Also, our findings are not suggestive of an
increased risk of breast cancer with the use of individual SSRIs.
Conclusions: Our study improved upon most previous studies by having a longer follow-up period, a larger
sample size of long-term SSRI users and consideration of risk during specific exposure time windows that take
latency into account. Given the potential health benefits of using SSRIs, our results suggest that the issue of breast
cancer risk may no longer be a concern for women requiring long-term SSRIs.
Background
Experimental evidence suggests that SSRIs, a popular
class of antidepressants, enhance breast cell proliferation
during a relatively late phase in breast cancer develop-
ment, either directly through SSRI tumour-promoting
mechanisms [1-3] or indirectly through an SSRI-
mediated increase in prolactin, a hormone for which
there is increasing evidence to suggest an association
with breast cancer [4,5].
Previous epidemiologic studies examining the relation-
ship between SSRI use and breast cancer were mainly
conducted in the 1990’s when the prevalence of SSRI
use was low and therefore those studies were limited by
a lack of subjects with prolonged use of SSRIs [6]. As
such, few epidemiologic studies have investigated the
long-term safety of SSRIs or considered a latent effect of
SSRI use on breast cancer risk. In a review, Coogan [6]
highlighted the ‘dearth of data’ related to long-term
SSRI use and breast cancer risk and recommended
further study. Given that breast cancer is the most fre-
quently diagnosed cancer in women [7,8] and that SSRIs
have now been on the market for more than 20 years
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women, further investigation of the potential association
between long-term SSRI use and breast cancer risk is
warranted.
In this study, we evaluated the effects of duration of
use, cumulative dose, and latency on breast cancer risk
using a population-based case-control study.
Methods
Data sources and linkage
This population-based case-control study utilized three
administrative health databases from the province of Sas-
katchewan (SK), Canada: (1) the person registry system
(PRS) (population registry) for information on demo-
graphics and dates of health coverage for the majority of
SK residents, (2) the Saskatchewan prescription drug
plan (SPDP) database for all outpatient prescriptions cov-
ered by the drug plan filled since the mid-1970’s for most
SK residents, and (3) the Saskatchewan Cancer Agency
(SCA) cancer registry database for detailed information
on cancer diagnoses since 1970 [9]. Information from all
three databases was available for approximately 91% of
residents (about one million people) since the remainder
have their prescription drug benefits covered by federal
government agencies. In Saskatchewan, the Health Ser-
vices Number (HSN) is a lifetime number that uniquely
identifies each resident eligible for provincial health
insurance coverage and enables complete record linkage
across databases and over time [9].
Selection of cases and controls
The underlying study population for cases and controls
was conceptualized as all women eligible for outpatient
prescription drug benefits who, during the case accrual
period 2003 to 2006, were aged 28 to 79, had prescrip-
tion coverage for 10 or more consecutive years prior to
their index date, and no previous cancer diagnosis at
any site in the 10 years preceding the index date, with
the exception of non-melanoma skin cancer and in situ
cervical cancer. We included all incident cases of pri-
mary invasive breast cancer, diagnosed between 1 Janu-
ary 2003 and 31 December 2006, who met the eligibility
criteria listed above. Controls were selected from the
underlying study population using an incidence density
(or risk-set) sampling approach [10]. Briefly, the four-
year case accrual period was divided into eight sampling
periods each of six months duration to define the risk
sets from which women who were still at risk of the
event (controls) were chosen. Ten controls per case, fre-
quency-matched on cases’ age in five-year groups, were
randomly selected from each risk set. The index date for
cases was the date of breast cancer diagnosis, and for
controls it was a randomly chosen date within each six-
month sampling period.
We initially identified 1,702 women diagnosed with
breast cancer (1,699 (99.8%) primary invasive cancers
and 3 (0.2%) carcinomas in situ), (the latter were
retained in the analysis because of their small numbers)
between 1 January 2003 and 31 December 2006 and
17,020 matched controls. One case and three controls
were excluded from the analysis because of missing
demographic data leaving 1,701 cases and 17,017
controls.
SSRI use
Information was obtained on all SSRI prescriptions dis-
pensed for cases and controls between the start of their
drug plan coverage or 1 July 1989 (when the first SSRI
was listed on the SK Formulary), whichever was later,
and the index date. SSRIs covered by the provincial
drug plan during the study period included citalopram,
fluoxetine, fluvoxamine, paroxetine and sertraline and
were available with no prescribing restrictions. SSRIs
were first considered as a group, then as individual
agents. Data extracted from the prescription drug data-
base included the dispensing date, name, strength,
dosage formulation, and quantity of the SSRI dispensed.
The prescription database did not include information
on the dosage prescribed (pills per dose and total num-
ber of doses per day), the duration of each prescription,
or the indication for the SSRI prescription.
The observation period was divided into three expo-
sure time windows of interest. First, breast cancer risk
w a se x a m i n e di nr e l a t i o nt ot o t a lS S R Iu s ed u r i n gt h e
exposure time period two or more years prior to index
date thereby representing a two-year latency between
SSRI use and breast cancer diagnosis. SSRI use within
two years of index date was not considered etiologically
relevant and was therefore excluded from the analysis
similar to previous studies [11,12], and supported by
models of tumour growth [13] and experimental labora-
tory evidence of an SSRI promoter effect on breast can-
cer development [1]. In addition, exclusion of this
biologically irrelevant SSRI exposure period minimized
the potential for reverse causality bias (when SSRI use is
associated with cancer that is already present but not
clinically detectable).
To further evaluate the effect of latency on the asso-
ciation between SSRI use and breast cancer risk, the
exposure time window two or more years prior to the
index date was subdivided into two shorter mutually
exclusive exposure time windows chosen ap r i o r i(two
to seven years preceding index date representing a two-
year latency and more than seven years prior to index
date representing a latency of seven years). We hypothe-
sized that either prolonged SSRI use within the time
period two to seven years or more than seven years
prior to index date may be associated with increased
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ined only in relation to SSRI use over the exposure time
window two or more years prior to index date. The
comparator group for each of these analyses was women
with no SSRI prescriptions (non-use of SSRIs) during
the specific exposure time window being analyzed.
Two measures of cumulative SSRI use were used:
duration (total number of prescriptions dispensed) and
cumulative dose (total dosage received). These were
modelled as categorical variables in order to facilitate
the analysis of the most clinically relevant contrast, that
is, long-term users versus non-users.
Duration of use for all SSRIs combined was based on
the total number of SSRI prescriptions dispensed in
each of the SSRI exposure time windows of interest
(two or more years, two to seven years or more than
seven years prior to index date). Since SSRI prescrip-
tions in Saskatchewan are typically dispensed to
accommodate a 34-day treatment period, this measure
of SSRI use approximated the number of months
exposed. For each exposure time period, duration of
SSRI use was categorized on the basis of clinically rele-
vant cut-offs with the intention of creating an upper-
most category of SSRI users that included an adequate
number of subjects. For the time periods two or more
years and two to seven years prior to the index date,
duration of SSRI was categorized as never, 1 to 35 pre-
scriptions and ≥36 prescriptions. Due to the smaller
number of subjects who had used SSRIs in the period
of time more than seven years prior to index date,
exposure categories chosen were never, 1 to 23 and
≥24 prescriptions.
The cumulative dose of SSRIs was calculated in terms
of fluoxetine-equivalent milligrams for each prescription
using the defined daily doses (DDD) published by the
World Health Organization [14] and summed across all
prescriptions. The DDD is a unit of measurement that
allows comparisons of therapeutic intensity between
medications from the same therapeutic class [15]. The
DDD fluoxetine-equivalent dosages for the five SSRIs
included in this study were: 20 milligrams (mg) of fluox-
etine = 20 mg of citalopram = 20 mg of paroxetine = 50
mg of sertraline = 100 mg of fluvoxamine [14].
Although it may be debated whether fluoxetine-equiva-
lent dosages are representative of the carcinogenic
potential of individual agents, this measure of SSRI use
was chosen so that the cumulative dose could be inter-
preted in the context of clinically relevant dosages.
Total dosages were categorized as no use, low dose
(< 85
th percentile) and high dose (≥85
th percentile) based
on the distribution of total dosages among exposed con-
trols for each of the three exposure time windows. This
cut-off was chosen to identify a comparable group of
highly exposed individuals to that used in the duration of
use (number of prescriptions) analysis.
For the analysis of individual SSRIs, duration of use
was represented by the total number of prescriptions
dispensed and limited to SSRI use two or more years
prior to index date because of small sample sizes. ‘Any
use’ referred to women who had used the individual
SSRI of interest alone or in combination with one or
more other SSRIs, whereas ‘exclusive use’ referred to the
subset of ‘any use’ who had used only one type of SSRI
during the study period.
Potential confounders
Using yearly demographic data available from the popu-
lation registry, subjects were categorized for marital
status (married, single, other), residence status (urban,
rural) and income support status (no support, low sup-
port, and high support) (See Table 1 footnotes for
details). As previously mentioned, we frequency-
matched on age at index date in five-year groups and
adjusted for age (continuous).
Medication history for use of oral contraceptives
(OCs) and hormone therapy (HT) was compiled for the
period between (a) 1 September 1975 (the year that the
SPDP database was started) or (b) the date of prescrip-
tion coverage initiation, (whichever occurred later), and
the subject’s index date (See Table 1 footnotes for
details). OC and HT prescription data were not available
from July 1987 to December 1988 when pharmacy data
were recorded by family unit rather than by the indivi-
dual [9]. Consistent with the approach taken for SSRI
exposures, use of OCs and HT within two years of the
index date was excluded.
Statistical analysis
Unconditional logistic regression was conducted to
evaluate the impact of duration of combined SSRI use
(total number of prescriptions dispensed), cumulative
dose (total dosage received) and timing of use (two or
more years, two to seven years and more than seven
years prior to index date) on the risk of breast cancer.
For each individual SSRI, duration of use (total num-
ber of prescriptions dispensed) was analyzed only for
the time period two or more years prior to index date.
To evaluate potential confounders, the ‘change in esti-
mate’ method was used with a ≥10% criterion for
inclusion [16,17]. No covariate tested (age - continu-
ous, marital status, residence, income support status,
oral contraceptive and hormone therapy use - categori-
cal) met the definition of a confounder. However, we
chose to use a fully adjusted model for each analysis
since there was no loss of precision compared to the
parsimonious model.
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The study population consisted of 1,701 cases and
17,017 controls. Cases were diagnosed at a mean age of
60.4 years (SD 11.5) and represented a homogeneous
group with respect to morphology, with approximately
75% having infiltrating ductal carcinoma, 10% lobular
carcinoma, and 15% with a mix of other morphologies.
There was more variability in relation to stage at diag-
nosis, with 44.9% of cases presenting as stage one, 35.3%
stage two, 12.6% stage three, 4.5% stage four, 0.2% in
Table 1 Characteristics of cases and age-matched controls
Characteristic Cases (N = 1701) Controls (N = 17017) Unadjusted OR
a
(95% CI)
n (%) n (%)
Age (yrs)
Mean (SD) 60.4 (11.5) 60.3 (11.6) 1.00 (1.00, 1.01)
Age categories
<40 (%) 50 (2.9) 500 (2.9) 1.00
40-55 (%) 540 (31.8) 5500 (32.3) 1.01 (0.75, 1.36)
>55 (%) 1111 (65.3) 11017 (64.7) 0.98 (0.73, 1.33)
Follow-up (yrs)
b
Mean (SD) 28.4 (3.3) 28.4 (3.5) 1.03 (1.00, 1.06)
Median (range) 29 (10,31) 29 (10,31)
Marital Status
c
Other (widowed, separated, divorced) 309 (18.2) 3565 (21.0) 1.00
Single 108 (6.4) 1111 (6.5) 1.12 (0.89, 1.41)
Married 1284 (75.4) 12341 (72.5) 1.20 (1.05, 1.37)
Income support status
d
No income support 1232 (72.4) 12088 (71.0) 1.00
Low income support 412 (24.2) 4235 (24.9) 0.96 (0.85, 1.07)
High income support 57 (3.4) 694 (4.1) 0.81 (0.61, 1.06)
Residence status
e
Urban 731 (43.0) 6984 (41.0) 1.00
Rural 970 (57.0) 10033 (59.0) 0.92 (0.84, 1.02)
OC use
f
None or light use (<12 prescriptions) 1318 (77.5) 13557 (79.7) 1.00
Heavy use (≥ 12) 383 (22.5) 3460 (20.3) 1.14 (1.01, 1.28)
HT use
f
None or light use (<12 prescriptions) 1200 (70.6) 12441 (73.1) 1.00
Heavy use (≥12) 501 (29.4) 4576 (26.9) 1.14 (1.02, 1.27)
OR = odds ratio; CI = confidence interval; OCs = oral contraceptive(s); HT = hormone therapy.
a Frequency-matched on age in five-year groups but not adjusted for the influence of other risk factors.
b Follow-up: Number of years eligible to receive outpatient prescription drug benefits in Saskatchewan.
c Marital status: attributed to the marital state six years prior to index date.
d Income support status: based on yearly demographic data and assigned to one of three categories based on the greatest proportion of time having received
income support: that is, no income support, ≤50% of time receiving income support = low income support, and >50% of time receiving income support = high
income support.
e Residence status: based on yearly demographic data and assigned based on the greatest proportion of time spent in a given residence state: that is, ≤50% of
time in urban location (population >100,000) = rural residence status and >50% of time as urban = urban residence status.
f OC and HT use: defined as total number of prescriptions two or more years prior to index date. These drugs are typically dispensed as a two-month supply;
therefore, in most cases, 12 prescriptions would correspond to a two-year supply. All oral and injectable contraceptives were included as were all hormone
therapy formulations except vaginal creams and rings.
Note: Percentages may not add up to 100% due to rounding.
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The proportion of breast cancer cases diagnosed each
year was similar across the four-year accrual period.
Cases and controls were followed for an average of
28.4 years and were similar with regard to age, income
support, and residence status (Table 1). However, cases
were more likely than controls to be married and to
have used hormone therapy and/or oral contraceptives.
Table 2 shows the unadjusted and adjusted ORs and
95% CIs for breast cancer risk according to the number
of SSRI prescriptions dispensed for all SSRIs combined
during each of three exposure time windows of interest
(two or more years, two to seven years and more than
seven years prior to index date). After adjustment for
risk factors, women who had filled ≥36 prescriptions
(estimated SSRI use of three or more years) in the time
period two or more years prior to index date were not
at increased risk of developing breast cancer compared
to non-users (OR = 1.03, CI = 0.75 - 1.41). Similarly,
long-term use of SSRIs during the exposure time period
two to seven years or more than seven years before the
index date was not associated with an increased risk of
breast cancer compared to non-users (OR = 1.13, CI =
0.78 - 1.64, and OR = 0.80, CI = 0.49 - 1.29, respec-
tively). A shorter duration of use was also not associated
with an increased risk of breast cancer regardless of the
time period evaluated.
Compared with no use of SSRIs, higher total dosages
(based on fluoxetine-equivalent dosages for all SSRIs
combined) did not increase the risk of breast cancer
during each exposure time window of interest, that is,
two or more years prior to index date (OR = 0.91, CI
= 0.64 - 1.28), two to seven years prior to index date
(OR = 0.92, CI = 0.62 - 1.36) and use more than seven
years prior to index date (OR = 1.02, CI = 0.67 - 1.55)
(Table 3). Similarly, lower dosages were not associated
with an increased risk in any time period assessed.
The pattern of risk observed with the use of indivi-
dual SSRIs was similar to that for all SSRIs combined
(Table 4 and 5). Overall, there was no evidence of
increased risk of breast cancer associated with ‘any use’
of individual SSRIs, regardless of the total number of
prescriptions dispensed (Table 4). The small number
of users of specific SSRIs did not permit an evaluation
of risk associated with their use during the two shorter
exposure windows. The odds ratios for ‘exclusive use’ of
high doses of paroxetine (OR = 1.20, CI = 0.64 - 2.25),
sertraline (OR = 1.84, CI = 0.86 - 3.93) and fluvoxamine
(OR = 1.33, CI = 0.47 - 3.77) failed to rule out the pos-
sibility of an increased risk; however, the number of
exclusive users of any one agent was small and the cor-
responding confidence intervals very wide (Table 5).
Discussion
This large population-based case-control study utilized
administrative health databases to assess SSRI use and
breast cancer risk in relation to duration of use, cumula-
tive dose and latency; critical considerations within the
context of a carcinogenic hypothesis [18]. Overall, SSRI
use was not associated with an increased risk of breast
cancer regardless of our definition of cumulative use
(total number of prescriptions dispensed and total
dosage). In addition, our results indicate that prolonged
SSRI use does not have a latent effect on breast cancer
Table 2 Odds ratios for breast cancer according to duration of SSRI use during exposure time windows
Exposure time window
a No. of SSRI prescriptions Cases (n = 1,701) Controls (n = 17,017) Unadjusted OR
b
(95% CI)
Adjusted OR
c
(95% CI)
n (%) n (%)
≥2 years No use
d (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
1 to 35 215 (12.6) 2,178 (12.8) 0.99 (0.85, 1.15) 0.98 (0.84, 1.14)
≥36 44 (2.6) 424 (2.5) 1.04 (0.76, 1.42) 1.03 (0.75, 1.41)
2 to 7 years No use
d (reference) 1,512 (88.9) 15,122 (88.9) 1.00 1.00
1 to 35 157 (9.2) 1,614 (9.5) 0.97 (0.82, 1.16) 0.97 (0.82, 1.15)
≥36 32 (1.9) 281 (1.7) 1.14 (0.79, 1.65) 1.13 (0.78, 1.64)
>7 years No use
d (reference) 1,556 (91.5) 15,528 (91.3) 1.00 1.00
1 to 23 127 (7.5) 1,266 (7.4) 1.00 (0.83, 1.21) 1.00 (0.82, 1.21)
≥24 18 (1.0) 223 (1.3) 0.81 (0.50, 1.31) 0.80 (0.49, 1.29)
OR = odds ratio; CI = confidence interval.
a Prior to index date.
b Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
c Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
d ’No use’ (reference category) refers to women with no SSRI prescriptions dispensed during the specified time period evaluated.
Note: Percentages may not add up to 100% due to rounding.
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Exposure time window
a Total SSRI dosage
b
(mg)
Cases (n = 1,701) Controls (n = 17,017) Unadjusted OR
c
(95% CI)
Adjusted OR
d
(95% CI)
n (%) n (%)
≥2 years No use
e (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
1 to 27, 750 mg 222 (13.1) 2,198 (12.9) 1.01 (0.87, 1.17) 1.01 (0.87, 1.17)
≥27, 750 mg 37 (2.2) 404 (2.4) 0.92 (0.65, 1.29) 0.91 (0.64, 1.28)
2 to 7 years No use
e (reference) 1,512 (88.9) 15,122 (88.9) 1.00 1.00
1 to 25, 365 mg 161 (9.5) 1,594 (9.4) 1.01 (0.85, 1.20) 1.01 (0.85, 1.20)
≥25, 365 mg 28 (1.7) 301 (1.8) 0.93 (0.63, 1.38) 0.92 (0.62, 1.36)
>7 years No use
e (reference) 1,558 (91.6) 15,475 (90.9) 1.00 1.00
1 to 20, 340 mg 118 (6.9) 1,303 (7.7) 0.90 (0.74, 1.09) 0.90 (0.74, 1.09)
≥20, 340 mg 25 (1.5) 239 (1.4) 1.04 (0.69, 1.57) 1.02 (0.67, 1.55)
OR = odds ratio; CI = confidence interval.
a Prior to index date.
b Combined dosage calculated using fluoxetine-equivalent dosages according to the World Health Organization’s defined daily doses (DDD) methodology.
c Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
d Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
e ‘No use’ (reference category) refers to women with no SSRI prescriptions dispensed during the specified time period evaluated.
Note: Percentages may not add up to 100% due to rounding.
Table 4 Odds ratios for breast cancer according to duration for ‘any use’ of individual SSRIs
No. of SSRI
prescriptions
Any use
a
Cases Controls Unadjusted OR
b
(95% CI)
Adjusted OR
c
(95% CI)
n (%) n (%)
No use
d (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
Paroxetine
1 to 23 94 (6.0) 893 (5.8) 1.05 (0.85, 1.31) 1.05 (0.84, 1.31)
≥24 20 (1.3) 184 (1.2) 1.09 (0.68, 1.73) 1.06 (0.67, 1.69)
Sertraline
1 to 23 46 (3.1) 518 (3.5) 0.89 (0.65, 1.21) 0.89 (0.65, 1.21)
≥24 10 (0.7) 103 (0.7) 0.97 (0.51, 1.86) 0.98 (0.51, 1.89)
Fluoxetine
1 to 23 82 (5.3) 893 (5.8) 0.92 (0.72, 1.64) 0.92 (0.71, 1.64)
≥ 24 25 (1.6) 231 (1.5) 1.08 (0.71, 1.64) 1.08 (0.71, 1.64)
Fluvoxamine
1-23 45 (3.0) 411 (2.8) 1.10 (0.80, 1.50) 1.10 (0.80, 1.51)
≥24 4 (0.3) 52 (0.4) 0.77 (0.28, 2.13) 0.78 (0.28, 2.18)
Citalopram
1 to 23 27 (1.8) 314 (2.1) 0.86 (0.58, 1.28) 0.85 (0.57, 1.27)
≥24 3 (0.2) 23 (0.2) 1.30 (0.39, 4.35) 1.28 (0.38, 4.27)
OR = odds ratio; CI = confidence interval.
a ’Any use’ refers to use of individual SSRI of interest alone or in combination with one or more other SSRIs during the exposure time window two or more years
prior to index date.
b Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
c Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
d ’No use’ (reference category) refers to women with no SSRI prescriptions dispensed two or more years prior to index date.
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increased risk of breast cancer with the use of individual
SSRIs.
Our study improved upon most previous studies by
having a longer follow-up period (subjects were followed
for up to 18 years after initial SSRI exposure) and pro-
spectively collected drug information that afforded pre-
cise and objective exposure definitions. Further, few
previous studies assessed risk associated with long-term
use of SSRIs of comparable duration (that is, the equiva-
lent of three or more years of use) or during specific
exposure time windows that take latency into account.
However, despite these methodological improvements,
our results are consistent with most other observational
studies, including six that used self-reported SSRI expo-
sure information [19-24], and four studies that ascer-
tained SSRI use from a prescription database [25-28].
However, only three of these studies [22,24,27] had suf-
ficient sample sizes to adequately evaluate risk asso-
ciated with three or more years of combined SSRI use,
and only one study [27] quantified total SSRI use with a
dosage variable.
Haukka et al. [29] in a record-linkage study investigat-
ing cancer incidence at 19 sites in relation to the use
of several antidepressants, reported an RR of 1.53
(CI = 1.14 - 2.05) for breast cancer for subjects with
more than four years of SSRI use compared to non-
users, adjusted for age and sex. However, this result
may be due to residual confounding or Type 1 error
since more than 275 analyses were performed.
No previous peer-reviewed published studies have
considered a delayed effect of SSRI exposure using simi-
lar time periods. However, results from other studies
that assessed the effect of timing of SSRI use on breast
cancer risk using less precise measures of past SSRI use,
such as ‘time since first use’ or ‘time since last use’
[19,20,28] or ‘current’ versus ‘former’ users [22-24,27]
are consistent with our null findings.
Our findings of no increased risk of breast cancer for
long-term use of individual SSRIs were consistent with
most other observational studies that specifically
assessed these relationships [22,23,26-28], but contrary
to a non-significant dose-response decrease in risk asso-
ciated with increasing duration of paroxetine use
reported by Wernli et al.[ 2 4 ]( P-trend = 0.10).
Although the associations for ‘exclusive use’ of high
doses of paroxetine, sertraline and fluvoxamine were
inconclusive, it is important to remember that the confi-
dence intervals were wide and less than 1% of women in
our study had used these agents exclusively for two
Table 5 Odds ratios for breast cancer according to duration for ‘exclusive use’ of individual SSRIs
No. of SSRI
prescriptions
Exclusive use
a
Cases Controls Unadjusted OR
b
(95% CI)
Adjusted OR
c
(95% CI)
n (%) n (%)
No use
d (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
Paroxetine
1 to 23 57 (3.8) 482 (3.2) 1.18 (0.89, 1.56) 1.17 (0.88, 1.55)
≥24 11 (0.73) 89 (0.6) 1.24 (0.66, 2.32) 1.20 (0.64, 2.25)
Sertraline
1 to 23 22 (1.5) 240 (1.6) 0.92 (0.59, 1.42) 0.92 (0.59, 1.42)
≥24 8 (0.5) 44 (0.3) 1.82 (0.85, 3.87) 1.84 (0.86, 3.93)
Fluoxetine
1 to 23 38 (2.6) 483 (3.2) 0.79 (0.56, 1.10) 0.79 (0.56, 1.10)
≥24 1 (0.7) 134 (0.9) 0.82 (0.44, 1.52) 0.81 (0.44, 1.51)
Fluvoxamine
1 to 23 18 (1.2) 174 (1.2) 1.03 (0.64, 1.69) 1.02 (0.63, 1.67)
≥24 4 (0.3) 30 (0.2) 1.33 (0.47, 3.79) 1.33 (0.47, 3.77)
Citalopram
e
1 to 23 9 (0.6) 133 (0.9) Not estimatable Not estimatable
≥24 0 (0.0) 9 (0.1)
OR = odds ratio; CI = confidence interval.
a ’Exclusive use’ refers to use of only one type of SSRI during the exposure time window two or more years prior to index date.
b Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
c Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
d ’No use’ (reference category) refers to women with no SSRI prescriptions dispensed two or more years prior to index date.
e Small sample sizes did not allow a complete evaluation of risk for ‘exclusive use’ of citalopram.
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not a source of concern.
T h ev a l i d i t yo fo u rs t u d yi sh i g hf o rs e v e r a lr e a s o n s .
The Saskatchewan databases are recognized as valuable
resources for drug utilization review and pharmacoepi-
demiologic studies [9,30] with built-in audit and eligibil-
ity checks and good cross database integrity for the
conditions studied [9]. The advantages of using a pre-
scription database compared to self-reported SSRI use
f o rd r u ge x p o s u r ei n f o r m a t i o ni n c l u d er e l a t i v e l ye a s y
access to large sample sizes and elimination of exposure
recall error and bias [9,31,32]. In addition, with the use
of detailed prescription database exposure histories,
more precise SSRI exposure measures were calculated to
represent duration and dosage of long-term use, allow-
i n gu st oa s s e s st h el a t e n te f fects of chronic long-term
SSRI use more accurately. Lack of selection bias is also
a major strength of this study since there is virtually
complete case ascertainment, and controls had a known
and equal probability of being randomly selected from
the same underlying population as the cases during the
same time interval.
By focusing on assessing risk associated mainly with
long-term SSRI use, it was anticipated that misclassifi-
cation due to non-compliance (primarily overestima-
tion of exposure) would more likely occur within the
low exposure categories (one or two prescriptions
filled), rather than in the contrast of most interest (for
example, ≥36 prescriptions versus no exposure). That
is, if prescriptions were repeatedly refilled, we assume
that they were more likely to be consumed. Therefore,
especially within the higher exposure group, misclassi-
fication of non-users of SSRIs as users would be less
likely. Further, non-compliance with dispensed medica-
tions would likely affect cases and controls equally in
this study, leading to non-differential misclassification,
if any.
The Saskatchewan prescription database lacked infor-
mation on SSRI medications dispensed in hospitals or as
samples from physicians [9]. Also, escitalopram, the
newest SSRI to become available in Canada (since late
2005), was not included in the SK Drug Formulary at
the time of data collection. However, it was anticipated
that the degree of potential misclassification (underesti-
mation of exposure) associated with these additional
sources of information bias would be uniform across the
case and control groups. Also, since the prescription
database does not include information on the prescribed
daily dosage regime, the total number of prescriptions
dispensed was used to estimate duration of SSRI use
based on the assumption that each prescription repre-
sented a 34-day supply. To indirectly test the extent of
misclassification related to estimating duration of
exposure using number of prescriptions, risk was esti-
mated for total dosage of combined SSRI use: none was
detected, confirming that exposure classification errors
in relation to using number of prescriptions were
unlikely.
The SK databases did not contain information on
some determinants of breast cancer including repro-
ductive history, family history of breast cancer, anthro-
pometric variables and lifestyle factors. However,
residual confounding is unlikely to be a concern in our
study since previous studies of the SSRI-breast cancer
association that have collected information on these
factors have demonstrated that they are not a source
of confounding bias [19,21,23,33]. In addition, we did
not have information on prescription and over-the-
counter use of non-steroidal anti-inflammatory drugs
(NSAIDs), some of which have been associated with a
reduction in breast cancer risk. If NSAIDs were used
to a greater extent by SSRI users, then our risk esti-
mates may have been affected by uncontrolled con-
founding. However, we have no reason to believe that
this was the case.
Given that SSRIs are mainly prescribed for the treat-
ment of depression [34], and that there is a hypothesis
that the risk of breast cancer may be increased with
chronic depression [35,36], it may be contended that
residual confounding by depression may have biased
the results towards finding an association between
long-term SSRI use and breast cancer. However, since
our results demonstrate no increased risk, this source
of confounding “by indication” is of less concern.
Further, physician prescribing practices for SSRIs are
unlikely to be biased by the presence of established
risk factors for breast cancer, such as family history
and reproductive factors, since an association between
the use of SSRIs and breast cancer has not been firmly
established.
Conclusions
In conclusion, few epidemiologic studies have investi-
gated the long-term safety of SSRIs or considered a
latent effect of SSRI use on breast cancer risk. Using
precise and objective SSRI exposure measures of long-
term use that took into account the duration, dosage
and timing of SSRI use, our results do not indicate
that the risk of breast cancer is increased with short-
or long-term use of SSRIs or provide evidence of a
latent effect of past SSRI use. Given the potential
health benefits of using SSRIs, our results have impor-
tant implications within the realm of clinical medicine,
suggesting that the issue of breast cancer risk may no
longer be a concern for women requiring long-term
use of SSRIs.
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